Hydroxychloroquine News and Research

RSS

Study explores therapeutic potential of exploiting autophagy cascade against COVID-19

Researchers recently reviewed current knowledge on links between autophagy and coronaviruses and how this knowledge can be used to repurpose autophagy modulators as potential treatment options for COVID-19. The review is published in the journal Frontiers in Microbiology.

7 Jun 2021

Hydroxychloroquine + Azithromycin therapy at a higher dose improved survival by nearly 200% in ventilated COVID patients

However, a fascinating new study posted to the medRxiv* preprint server suggests that such disappointment may have been both premature and unwarranted, based on a re-analysis of over 250 patients on invasive mechanical ventilation (IMV) during the first two months of the pandemic.

2 Jun 2021

Effect of COVID-19 pandemic on patients with rheumatoid arthritis, systemic lupus erythematosus

In the Philippines, in the early months of the COVID-19 pandemic, there occurred a supply shortage of hydroxychloroquine and methotrexate. Limited access to medication and the life changes caused from the COVID-19 pandemic may prompt patients with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE) to experience disease flares.

29 May 2021

Simple at-home taste test could predict duration and severity of SARS-CoV-2 symptoms

A JAMA Network Open research paper published today (26 May 2021) by Doctorpedia contributor Henry P. Barham, M.D correlating an association between the bitter taste receptor phenotype and clinical outcomes among patients with COVID-19 has confirmed that a simple at-home taste test could be a gamechanger in predicting duration and symptom severity of the virus.

29 May 2021

New favipiravir derivative is a potent SARS-CoV-2 inhibitor

In a new study recently published in Chemical Papers by Dr. Amgad Rabie (May 16th, 2021), a high potency derivative of favipiravir towards SARS-CoV-2 is engineered and investigated.

27 May 2021

Are COVID-19 medications safe in pregnancy?

Most medications being tested today in clinical trials for the treatment of coronavirus disease 2019 (COVID-19) have been repurposed from other indications. These are typically not tested in pregnant women. A new study, published in the journal PLOS ONE, summarizes what is known about the safety of these drugs in this group.

24 May 2021

Genetically engineered intestinal organoids reveal potential treatment targets against SARS-CoV-2

Using CRISPR/Cas9 and human intestinal organoids to study genes implicated in the biology of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), researchers from the Netherlands identified a specific serine protease (TMPRSS2) as an attractive pan-coronavirus therapeutic target. Their exciting findings are available in a study currently available on the bioRxiv* preprint server.

24 May 2021

Investigators map how drugs were used on people hospitalized with COVID-19 infection

A record of medicine utilization patterns assembled by an interdisciplinary team of researchers at the University of California, Irvine and the UC San Diego School of Medicine reveals the thought, care and scientific rigor clinicians at UC Health medical centers applied in their treatment of patients with COVID-19 in 2020.

21 May 2021

Facets of SARS-CoV-2 infection and animal models

A new study in the journal Frontiers in Cell and Developmental Biology discusses the ribonucleic acid (RNA) genome of the virus, and the mechanisms by which it establishes infection within the host cell. The researchers also summarize the development of animal models of COVID-19, which will both help understand the clinical features of the illness, and indicate new approaches for the treatment of the infection.

21 May 2021

Could graphene oxide nanosheets be an effective SARS-CoV-2 antiviral in PPE?

A new study has been published in Small, which has combined in silico and in vitro analysis to examine if graphene oxide (GO) sheets have an inhibitory effect against SARS‐CoV‐2 surface proteins.

20 May 2021

SARS-CoV-2 UK variant more infectious because of higher viral load

The coronavirus disease 2019 (COVID-19) pandemic was triggered by the uncontrolled spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A year and a half later, the relationship between SARS-CoV-2 viral load and infectiousness remains a matter of scientific debate. Now, a new preprint research paper posted to the bioRxiv server aims to quantify this relationship

11 May 2021

ANTICOV clinical trial to test new treatment for people with mild-to-moderate COVID-19 in Africa

The ANTICOV clinical trial, conducted in 13 African countries, has started the recruitment of participants to test a new drug combination, nitazoxanide + ciclesonide, to treat people with mild-to-moderate COVID-19 before their cases become severe.

27 Apr 2021

What is the role of nanotechnology in the current COVID-19 outbreak?

The nanotechnology-based medicine platforms against COVID-19 bears hope for relief from the pandemic to save lives and mitigate the infection as part of a broader global public health agenda.

27 Apr 2021

Curcumin nanosystems could be powerful COVID-19 therapeutics

With new variants of SARS-CoV-2 emerging, the COVID-19 pandemic is far from over. While the global vaccine rollout has moved at an impressive speed, the search for new safe, effective, and targeted therapies is still on. Now, a new study reviews the potential for curcumin, a natural alkaloid derived from turmeric, and nanosystems to treat COVID-19.

16 Apr 2021

Scientists identify nine potential new COVID-19 treatments

A team led by scientists in the Perelman School of Medicine at the University of Pennsylvania has identified nine potential new COVID-19 treatments, including three that are already approved by the Food and Drug Administration (FDA) for treating other diseases.

2 Apr 2021

Scientists seek Covid treatment answers in cheap, older drugs

Could a decades-old antidepressant be a secret weapon against covid? A few scientists think so, after two small studies showed that fluvoxamine, typically prescribed for obsessive-compulsive disorder, prevented serious illness in all participants who took the pills soon after developing symptoms.

29 Mar 2021

Hydroxychloroquine News and Research

Study explores therapeutic potential of exploiting autophagy cascade against COVID-19

Hydroxychloroquine + Azithromycin therapy at a higher dose improved survival by nearly 200% in ventilated COVID patients

Effect of COVID-19 pandemic on patients with rheumatoid arthritis, systemic lupus erythematosus

Simple at-home taste test could predict duration and severity of SARS-CoV-2 symptoms

New favipiravir derivative is a potent SARS-CoV-2 inhibitor

Are COVID-19 medications safe in pregnancy?

Genetically engineered intestinal organoids reveal potential treatment targets against SARS-CoV-2

Investigators map how drugs were used on people hospitalized with COVID-19 infection

Facets of SARS-CoV-2 infection and animal models

Could graphene oxide nanosheets be an effective SARS-CoV-2 antiviral in PPE?

SARS-CoV-2 UK variant more infectious because of higher viral load

ANTICOV clinical trial to test new treatment for people with mild-to-moderate COVID-19 in Africa

What is the role of nanotechnology in the current COVID-19 outbreak?

Curcumin nanosystems could be powerful COVID-19 therapeutics

Scientists identify nine potential new COVID-19 treatments

Scientists seek Covid treatment answers in cheap, older drugs

Hydroxychloroquine has no effect in treating people with COVID-19, study shows

Hydroxychloroquine should not be used to prevent COVID-19, says WHO expert panel

Some nutritional supplements may help prevent or mitigate COVID-19 severity

New Cochrane Review: Hydroxychloroquine does not reduce deaths from COVID-19

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News